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Significance of this study
What is already known about this subject?
 ► Patients with type 1 diabetes (T1D) with impaired 
awareness of hypoglycemia (IAH) are in higher risk 
of severe hypoglycemia (SH).
 ► SH is associated with adverse clinical consequences 
and cerebral damage.
 ► There is no validated biomarker for this subgroup of 
patients.
What are the new findings?
 ► Plasma neurofilament light chain (NfL) levels were 
increased in patients with T1D- IAH compared to pa-
tients with T1D with normal awareness of hypogly-
cemia and healthy controls.
 ► Increased NfL levels correlated with reduced cere-
bral gray matter volume and increased IAH severity 
in patients with T1D- IAH.
How might these results change the focus of 
research or clinical practice?
 ► Plasma Nfl levels could be used as a non- invasive, 
cost- effective, and logistically efficient biomarker of 
neuroaxonal damage in patients with T1D- IAH.
AbStrAct
Introduction Impaired awareness of hypoglycemia (IAH) 
is a common complication in patients with type-1 diabetes 
(T1D). IAH is a major risk factor for severe hypoglycemic 
events, leading to adverse clinical consequences and 
cerebral damage. Non- invasive, cost- effective, and 
logistically efficient biomarkers for this condition have not 
been validated. Here, we propose plasma neurofilament 
light chain (NfL) levels as a biomarker of neuroaxonal 
damage in patients with T1D- IAH.
Research design and methods 54 patients were 
included into the study (18 T1D- IAH, 18 T1D with normal 
awareness of hypoglycemia (NAH) and 18 healthy 
controls). We measured plasma NfL levels and studied 
cerebral gray matter alterations on MRI.
Results We found that NfL levels were increased in 
patients with T1D- IAH compared with patients with T1D- 
NAH and healthy controls. Importantly, increased NfL levels 
correlated with reduced cerebral gray matter volume and 
increased IAH severity in patients with T1D- IAH.
Conclusion Overall, our findings identify plasma NfL 
levels as a potential biomarker of cerebral damage in this 
population, motivating further confirmatory studies with 
potential implications in clinical trials.
InTRoduCTIon
About one in five patients with type 1 diabetes 
(T1D) have impaired awareness of hypogly-
cemia (IAH).1 IAH represents a risk factor for 
severe and recurrent hypoglycemic events, 
which can lead to brain damage.2 3 As no effec-
tive treatment has been clearly established,4 
biomarkers capable of detecting and quanti-
fying cerebral damage in this population are 
needed for the design of novel preventive or 
therapeutic strategies.
On the one hand, cerebral atrophy or 
functional impairment can be assessed using 
neuroimaging techniques. In fact, a struc-
tural and functional brain compromise has 
been described in patients with T1D- IAH.5 
However, neuroimaging techniques have 
important limitations in terms of specificity, 
logistics, standardization, scalability, and 
cost- efficiency. On the other hand, while 
cerebrospinal fluid biomarkers of cerebral 
damage overcome some of these limitations, 
they require an invasive lumbar puncture 
procedure.
In recent years, research has focused 
on the detection of blood biomarkers of 
neural damage. Clearly, cost- efficient blood 
biomarkers would represent an accessible 
and centralizable alternative. However, the 
main challenge for the development of an 
adequate technology in this context has been 
the low blood concentration of proteins 
derived from the central nervous system 
(CNS). Importantly, in the last few years, the 
2 BMJ Open Diab Res Care 2020;8:e001516. doi:10.1136/bmjdrc-2020-001516
Pathophysiology/Complications
Single Molecule Array (Simoa) technology has shown 
unprecedented precision and sensitivity (ie, femtomolar 
range) for the quantification of blood biomarkers of brain 
damage.6 In particular, increased levels of neurofilament 
light chain (NfL) in blood have shown a great potential 
for the detection of neurodegeneration (neuronal loss 
and axonal damage), traumatic brain injury, and cere-
brovascular accidents.7
In this brief report, we investigate whether patients 
with T1D with hypoglycemia unawareness show increased 
levels of plasma NfL compared with patients with normal 
awareness of hypoglycemia (NAH) and healthy controls 
(HC). Additionally, we explore whether abnormally 
increased NfL levels in this population correlate with 




A total of 54 participants were included in this study: 
36 patients with T1D and 18 HC. Eighteen patients 
with T1D fulfilled clinical criteria for IAH (T1D- IAH) 
and the other 18 patients had NAH (T1D- NAH). Both 
T1D groups were selected as to have similar sociodemo-
graphics and T1D duration. The Clarke score was used for 
the IAH classification, which is based on eight questions 
that allow the determination of the glycemic threshold in 
which the patients notice the hypoglycemic symptoms.8 
A Clarke score ≥4 was used to identify patients with T1D- 
IAH, whereas patients with T1D- NAH showed a score <3. 
The Clarke method comprises the following set of ques-
tions designed to characterize the participant’s exposure 
to hypoglycemia: Do you feel hypoglycemia symptoms 
when your blood glucose is low?, Have you lost symptoms 
of hypoglycemia that used to occur when your blood 
glucose is low?, Check all your symptoms of hypoglycemia 
over the last 6 months, If your answered ‘yes’ to any of 
the above question, how often do you have it?, Check all 
your symptoms of hypoglycemia over the last 12 months. 
If your answered ‘yes’ to any of the above question, how 
often do you have it? How often did you have an episode 
of hypoglycemia with symptoms during the last month? 
How often did you have an episode of hypoglycemia 
without symptoms during the last month? What was the 
lowest blood glucose level before feeling the symptoms 
of hypoglycemia? How often did you have symptoms of 
hypoglycemia when your blood glucose level was low?
The following exclusion criteria were applied: previous 
clinical diagnosis of cognitive impairment or neurolog-
ical disorders, use of medications affecting the CNS, 
and MRI contraindications or intolerance. None of the 
participants in this study had any previous medical condi-
tion (apart from T1D) known to significantly alter blood 
NfL levels or cerebral GMV.
Both T1D groups were under similar insulin treat-
ment, either as basal- bolus regimen or continuous 
subcutaneous insulin infusion (with short- acting insulin 
analogs). Sociodemographic, clinical, and laboratory 
data (diabetes and cardiovascular indicators) were 
recorded for each patient. Quantification of IAH severity 
was assessed, on one hand, by Clarke scores. On the other 
hand, we also recorded the number of severe hypogly-
cemic episodes during the last 5 years and the number of 
moderate hypoglycemic events during the last month. A 
severe hypoglycemic episode associated loss of conscious-
ness, confusion/disorientation, seizures, or coma and 
required the assistance of a third person. A moderate 
hypoglycemic event was defined as any non- severe 
episode requiring the use of measures with impact on 
the daily life (interrupting work routine, stopping the car 
while driving, and so on). We combined both indicators 
to obtain a single indicator of the number of severe or 
moderate hypoglycemic episodes, providing a represen-
tative indicator of the clinical consequences of IAH.
Plasma nfl procedure
Blood was collected in EDTA tubes, centrifuged at 2000 g 
for 10 min and the plasma aliquoted in polypropylene 
tubes, and frozen at −80°C according to international 
consensus recommendations until analysis. Plasma NfL 
levels were measured with the Simoa Human NF- light 
Advantage kit using the Single Molecule Array tech-
nology (Simoa; Quanterix)9 in a SR- X Biomarker detec-
tion system by following the manufacturer’s instructions.
neuroimaging acquisition and preprocessing
T1- weighted MRI scans were acquired in a Philips 3- Tesla 
station using a magnetization- prepared rapid acquisition 
with gradient echo protocol using the following param-
eters: flip angle 8°, repetition time 6.7 s, echo time 3.19 
ms, pixel bandwidth 241, slice thickness 1.2 mm, and 
an acquisition matrix of size 256×256. All patients had 
available T1- MRI imaging, but nine subjects from the HC 
group did not have MRI data.
GMVs of the frontal, temporal, parietal, and occip-
ital lobes for each participant were computed using the 
FreeSurfer 6.0 software package. Details about the stan-
dard FreeSurfer segmentation pipeline are available 
elsewhere (https:// surfer. nmr. mgh. harvard. edu/). All 
preprocessed images were visually inspected to confirm 
the absence of segmentation errors.
statistical analyses
Clinical, sociodemographics, NfL levels, and imaging 
data were compared across groups using one- way ANOVA 
(except χ2 for sex differences). Pairwise group differ-
ences were examined by general linear models including 
age, sex, education, and T1D duration as covariates of no 
interest. A logistic regression was also performed. In addi-
tion, we explored whether increased plasma NfL levels 
correlated with increased IAH severity or reduced GMV 
in patients with T1D. For that, we used one- sided Pear-
son’s correlation coefficients using the same nuisance 
covariates, for which a p<0.05 was considered significant.
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Table 1 Clinical, demographic, biomarker, and imaging information across groups
T1D- IAH T1D- NAH HC
Significance 
(p value)
n 18 18 18
Age (years) 55.5±13.5 57.4±8.1 54.7±13.7 0.79
Sex (% female) 61% 27% 44% 0.13
Education (years) 14.8±5.1 14.7±4.4 13.6±3.5 0.64
Plasma NfL (pg/mL) 18.22±11.7 13.27±6.7 8.15±4.6 0.002*
T1D duration 31.7±12.8 30.2±8.6 NA 0.66
HbA1c (%) 7.57±1.1 7.60±0.8 NA 0.93
Body mass index (kg/m2) 25.9±6.6 27.2±3.8 NA 0.49
Mean arterial pressure (mm Hg) 93.6±15.6 101.8±13.6 NA 0.10
LDL- cholesterol (mg/dL) 96.3±27.4 94.6±21.3 NA 0.84
HDL- cholesterol (mg/dL) 71.4±16.5 63.7±19.1 NA 0.21
Clarke score 4.7±0.9 1.0±0.7 NA <0.001*
Number of severe or moderate hypoglycemic episodes 4.89±6.3 0.61±1.0 NA 0.007*
Minimental state examination 29.56±0.6 29.61±0.8 NA 0.81
Frontal lobe GMV (mm3×10–3) 138.6±9.9 150.3±13.5 165.0±17.6 <0.001*
Temporal lobe GMV (mm3×10–3) 93.0±7.2 102.3±9.7 100.8±9.6 0.007*
Parietal lobe GMV (mm3×10–3) 89.6±8.7 97.3±9.4 108.2±8.8 <0.001*
Occipital lobe GMV (mm3×10–3) 41.7±4.8 48.3±6.8 45.1±6.6 0.008*
Values are expressed as mean±SD or percentage.
*P<0.05 three- group ANOVA/χ2 or t- test between T1D groups.
ANOVA, analysis of variance; GMV, gray matter volumes; HC, healthy controls; HDL, high- density lipoprotein; IAH, impaired awareness of 
hypoglycemia; LDL, low- density lipoprotein; NA, not applicable or available; NAH, normal awareness of hypoglycemia; NfL, neurofilament 
light chain; T1D, type-1 diabetes.
ResulTs
Table 1 shows the sample characteristics of this study. All 
groups had similar sociodemographics. There were no 
significant differences between T1D groups in terms of 
disease duration, cognitive status, or cardiovascular risk 
factors. However, as expected, patients with T1D- IAH 
showed increased Clarke scores and number of severe 
or moderate hypoglycemic events in the last month, 
reflecting common clinical consequences of IAH.
Significant differences were found across groups in 
plasma NfL, progressively increasing from HC to T1D- 
NAH and T1D- IAH. Pairwise NfL differences between 
T1D- IAH and T1D- NAH were significant after controlling 
for age, sex, education, and disease duration (β=0.039, 
p=0.038). A logistic regression to classify patients with 
T1D- IAH versus T1- NAH including all factors listed in 
table 1 (except for Clarke scores and number of hypo-
glycemic episodes) yielded the following results. Signifi-
cance was only achieved by NfL levels (p=0.038), but the 
following close- to- significance factors were also observed: 
frontal GMV (p=0.062), temporal GMV (p=0.059), age 
(p=0.066), sex (p=0.064), and body mass index (p=0.054). 
Similarly, progressively decreasing GMV was observed 
across groups and cerebral lobules, and pairwise differ-
ences between T1D- IAH and T1D- NAH remained signif-
icant after controlling for the same nuisance covariates.
Finally, the following exploratory associations between 
increased NfL levels in patients with T1D and IAH severity 
and reduced cerebral GMV were observed. Within the 
T1D- IAH group, increased NfL levels correlated with 
lower frontal GMV (r=−0.51, p=0.030) and increased 
number of severe or moderate hypoglycemic events 
(r=0.49, p=0.038). When considering all patients with 
T1D, NfL levels correlated with Clarke scores (r=0.34, 
p=0.029) and the number of severe or moderate hypo-
glycemic events (r=0.45, p=0.005). Finally, although 
non- significant, NfL levels showed a mild association 
with temporal and parietal GMV (r=−0.28, p=0.051 and 
r=−0.21, p=0.11, respectively).
Figure 1 displays NfL differences across groups and a 
subset of these associations, using in some cases log NfL 
values to better illustrate group differences or correla-
tions, for which all statistical results remained significant.
dIsCussIon
Our results reinforce the presence of increased brain 
damage in patients with T1D- IAH. Plasma NfL levels were 
increased in this population and correlated with reduced 
cortical gray matter and IAH severity. Therefore, plasma 
NfL could be a promising cost- efficient biomarker of 
neural damage in patients with T1D- IAH.
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Figure 1 (A) Plasma NfL differences across groups (*p<0.05, **p<0.005). Scatter plots illustrating a subset of significant 
associations between NfL levels and (B) Clarke scores in patients with T1D, (C) frontal lobe GMV within the T1D- IAH group, and 
(D) number of severe or moderate hypoglycemic episodes within the T1D- IAH group. GMV, gray matter volumes; HC, healthy 
controls; IAH, impaired awareness of hypoglycemia; NAH, normal awareness of hypoglycemia; NfL, neurofilament light chain; 
T1D, type-1 diabetes.
Patients with T1D- IAH showed reduced cerebral GMV, 
especially in the frontal lobe. A frontal compromise has 
been previously described in this population, both in 
neuroimaging and cognitive studies.5 10 Importantly, in 
patients with T1D- IAH, increased NfL levels correlated 
with reduced frontal GMV. This association shows that 
increased NfL levels reflect cerebral damage in this 
population, reinforcing its role as a potential biomarker. 
Moreover, increased NfL levels were also associated with 
increased IAH severity, as measured by Clarke scores and 
also by the number of severe or moderate hypoglycemic 
events. This further emphasizes the clinical significance 
of increased NfL levels in this population, which probably 
reflect neural damage due to recurrent hypoglycemia.
The main strength of this study is the inclusion of 
patients with T1D- IAH and T1D- NAH with similar T1D 
duration and sociodemographic and cardiovascular 
profiles. This allowed studying the effect of IAH on NfL 
levels and cerebral GMV with high specificity. Limitations 
of this work include the use of a relatively low sample size, 
some missing data in the control group, and the explor-
atory character of the correlations between NfL levels 
and IAH severity and GMV within the T1D- IAH group.
To conclude, we found that plasma NfL levels are 
increased in patients with T1D- IAH, probably reflecting 
the presence of neuroaxonal damage with clinical conse-
quences. Overall, our findings motivate further confir-
matory studies on the potential role of this biomarker in 
this population, which could be used to predict IAH or 
monitor cerebral damage in clinical trials.
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